• about
  • DC IMMUNOTHERAPY
    • THE PRINCIPLE
    • ABOUT MESOPHER
    • PUBLICATIONS
  • pipeline
    • PLEURAL MESOTHELIOMA
    • PERITONEAL MESOTHELIOMA
    • PANCREATIC CANCER
  • partners & investors
  • news
  • contact
  1. Home
  2. Amphera news
  3. FDA Orphan Designation granted

FDA Orphan Designation granted

06 May 2014

On May 6, 2014 the FDA – the U.S. Food & Drug Administration – granted Amphera’s treatment of malignant mesothelioma Orphan Designation.

Previous EMA Orphan Designation granted
Next Amphera is moving to a new office
  • disclaimer
  • privacy policy

© 2019 Scicomvisuals, all rights reserved.